SELECT MEDICAL HOLDINGS CORP - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations. - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
February 23, 2023 Newswires
Share
Share
Post
Email

SELECT MEDICAL HOLDINGS CORP – 10-K – Management's Discussion and Analysis of Financial Condition and Results of Operations.

Edgar Glimpses

You should read this discussion together with the consolidated financial
statements and accompanying notes included elsewhere herein.


This section of this 10-K generally discusses 2022 and 2021 items and
year-to-year comparisons between 2022 and 2021. Discussions of 2020 items and
year-to-year comparisons between 2021 and 2020 that are not included in this
Form 10-K can be found in "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in Part II, Item 7 of the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2021.

Overview


We began operations in 1997 and, based on number of facilities, are one of the
largest operators of critical illness recovery hospitals, rehabilitation
hospitals, outpatient rehabilitation clinics, and occupational health centers in
the United States. As of December 31, 2022, we had operations in 46 states and
the District of Columbia. We operated 103 critical illness recovery hospitals in
28 states, 31 rehabilitation hospitals in 12 states, 1,928 outpatient
rehabilitation clinics in 39 states and the District of Columbia, 540
occupational health centers in 41 states, and 147 onsite clinics at employer
worksites as of December 31, 2022.

Our reportable segments include the critical illness recovery hospital segment,
the rehabilitation hospital segment, the outpatient rehabilitation segment, and
the Concentra segment. We had revenue of $6,333.5 million for the year ended
December 31, 2022. Of this total, we earned approximately 35% of our revenue
from our critical illness recovery hospital segment, approximately 14% from our
rehabilitation hospital segment, approximately 18% from our outpatient
rehabilitation segment, and approximately 27% from our Concentra segment. Our
critical illness recovery hospital segment consists of hospitals designed to
serve the needs of patients recovering from critical illnesses, often with
complex medical needs, and our rehabilitation hospital segment consists of
hospitals designed to serve patients that require intensive physical
rehabilitation care. Patients are typically admitted to our critical illness
recovery hospitals and rehabilitation hospitals from general acute care
hospitals. Our outpatient rehabilitation segment consists of clinics that
provide physical, occupational, and speech rehabilitation services. Our
Concentra segment consists of occupational health centers that provide workers'
compensation injury care, physical therapy, and consumer health services as well
as onsite clinics located at employer worksites that deliver occupational
medicine services.

                                       53

--------------------------------------------------------------------------------

Table of Contents

Non-GAAP Measure


We believe that the presentation of Adjusted EBITDA, as defined below, is
important to investors because Adjusted EBITDA is commonly used as an analytical
indicator of performance by investors within the healthcare industry. Adjusted
EBITDA is used by management to evaluate financial performance and determine
resource allocation for each of our segments. Adjusted EBITDA is not a measure
of financial performance under accounting principles generally accepted in the
United States of America ("GAAP"). Items excluded from Adjusted EBITDA are
significant components in understanding and assessing financial performance.
Adjusted EBITDA should not be considered in isolation, or as an alternative to,
or substitute for, net income, income from operations, cash flows generated by
operations, investing or financing activities, or other financial statement data
presented in the consolidated financial statements as indicators of financial
performance or liquidity. Because Adjusted EBITDA is not a measurement
determined in accordance with GAAP and is thus susceptible to varying
definitions, Adjusted EBITDA as presented may not be comparable to other
similarly titled measures of other companies.

We define Adjusted EBITDA as earnings excluding interest, income taxes,
depreciation and amortization, gain (loss) on early retirement of debt, stock
compensation expense, gain (loss) on sale of businesses, and equity in earnings
(losses) of unconsolidated subsidiaries. We will refer to Adjusted EBITDA
throughout the remainder of Management's Discussion and Analysis of Financial
Condition and Results of Operations.

The following table reconciles net income and income from operations to Adjusted
EBITDA and should be referenced when we discuss Adjusted EBITDA.

                                                                       For the Year Ended December 31,
                                                                 2020                  2021                2022
                                                                                (in thousands)
Net income                                                $    344,606             $  499,949          $  198,026
Income tax expense                                             111,867                129,773              62,553
Interest expense                                               153,011                135,985             169,111
Interest income                                                      -                 (5,350)                  -
Gain on sale of businesses                                     (12,387)                (2,155)                  -
Equity in earnings of unconsolidated subsidiaries              (29,440)               (44,428)            (26,407)

Income from operations                                         567,657                713,774             403,283
Stock compensation expense:
Included in general and administrative                          22,053                 24,598              30,555
Included in cost of services                                     5,197                  6,342               7,200
Depreciation and amortization                                  205,659                202,645             205,825
Adjusted EBITDA                                           $    800,566             $  947,359          $  646,863


                                       54

--------------------------------------------------------------------------------

Table of Contents

Effects of the COVID-19 Pandemic on our Results of Operations


The COVID-19 pandemic caused disruptions in each of our segments. These
disruptions were most significant within our outpatient rehabilitation and
Concentra segments, both of which experienced significant declines in patient
volume during the year ended December 31, 2020. Beginning in March 2021, these
segments began experiencing patient visit volumes which approximated or exceeded
the levels experienced in the months prior to the widespread emergence of
COVID-19 in the United States. As illustrated in the tables below, which present
revenue and certain operating statistics for each of our segments for the years
ended December 31, 2022, 2021, and 2020 as well as the comparable pre-COVID-19
pandemic period in 2019, our revenue and patient volume were only temporarily
impacted by the effects of COVID-19 pandemic.

Our businesses have, however, experienced other challenges exacerbated by the
pandemic, including constrained staffing due to a shortage of healthcare
workers, an increased usage of high-cost contract clinical workers, and
increased costs associated with retaining existing and recruiting new employees,
which have caused significant increases in our labor costs. The effects of these
challenges and other changes in the business environment on our segment
operating results are described further under "Management's Discussion and
Analysis of Financial Condition and Results of Operations-Results of
Operations."

Please refer to "Management's Discussion and Analysis of Financial Condition and
Results of Operations-Operating Statistics" for a discussion regarding the uses
and calculations of the metrics provided below.

                                               Critical Illness Recovery Hospital
                                                    Year Ended December 31,
                                   2019              2020              2021              2022
Revenue (in thousands)        $ 1,836,518       $ 2,077,499       $ 2,246,772       $ 2,234,132
Patient Days                    1,038,361         1,111,756         1,133,039         1,127,911
Occupancy Rate                         68  %             71  %             71  %             69  %
Number of Hospitals(1)                100                99               104               103


                                                Rehabilitation Hospital
                                                Year Ended December 31,
                                  2019            2020            2021            2022
Revenue (in thousands)        $ 670,971       $ 734,673       $ 849,340       $ 916,763
Patient Days                    353,031         370,833         414,701         430,547
Occupancy Rate                       76  %           78  %           83  %           85  %
Number of Hospitals(1)               19              19              20              20


                                                 Outpatient Rehabilitation
                                                  Year Ended December 31,
                                  2019             2020            2021             2022
Revenue (in thousands)        $ 1,046,011      $  919,913      $ 1,084,361      $ 1,125,282
Visits                          8,719,282       7,593,344        9,193,624        9,573,980
Working Days(2)                       255             256              254              255


                                                         Concentra
                                                  Year Ended December 31,
                                  2019             2020             2021             2022
Revenue (in thousands)        $ 1,628,817      $ 1,501,434      $ 1,732,041      $ 1,724,359
Visits                         12,068,865       10,627,904       12,052,724       12,579,468
Working Days(2)                       254              255              254              255

_______________________________________________________________________________
(1)  Represents the number of hospitals included in our consolidated financial
results at the end of each period presented and does not include the managed
hospitals in which we have a minority ownership interest.

(2) Represents the number of days in which normal business operations were
conducted during the periods presented.

                                       55

--------------------------------------------------------------------------------

Table of Contents

Summary Financial Results


Net income was $198.0 million, $499.9 million, and $344.6 million for the years
ended December 31, 2022, 2021, and 2020, respectively. Net income included
pre-tax gains on sales of businesses of $2.2 million and $12.4 million during
the years ended December 31, 2021 and 2020, respectively.

The following tables reconcile our segment performance measures to our
consolidated operating results for the years ended December 31, 2022, 2021, and
2020:

For the Year Ended December 31, 2022

                                   Critical Illness          Rehabilitation            Outpatient             Concentra             Other               Total
                                  Recovery Hospital             Hospital             Rehabilitation
                                                                                           (in thousands)
Revenue                           $   2,234,132            $       916,763          $    1,125,282          $ 1,724,359          $ 333,002          $ 6,333,538
Operating expenses                   (2,127,233)                  (718,970)             (1,023,422)          (1,392,475)          (491,096)          (5,753,196)
Depreciation and amortization           (61,565)                   (27,814)                (32,663)             (73,667)           (10,116)            (205,825)
Other operating income                    4,445                        241                       -                  312             23,768               28,766
Income (loss) from operations            49,779                    170,220                  69,197              258,529           (144,442)             403,283
Depreciation and amortization            61,565                     27,814                  32,663               73,667             10,116              205,825
Stock compensation expense                    -                          -                       -                2,141             35,614               37,755

Adjusted EBITDA                   $     111,344            $       198,034          $      101,860          $   334,337          $ (98,712)         $   646,863
Adjusted EBITDA margin                      5.0    %                  21.6  %                  9.1  %              19.4  %                N/M              10.2  %


                                                                                For the Year Ended December 31, 2021
                                   Critical Illness          Rehabilitation            Outpatient             Concentra             Other               Total
                                  Recovery Hospital             Hospital             Rehabilitation
                                                                                           (in thousands)
Revenue                           $   2,246,772            $       849,340          $    1,084,361          $ 1,732,041          $ 292,001          $ 6,204,515
Operating expenses                   (1,998,660)                  (664,636)               (946,086)          (1,379,566)          (443,176)          (5,432,124)
Depreciation and amortization           (53,094)                   (27,677)                (29,592)             (82,210)           (10,072)            (202,645)
Other operating income                   19,881                          -                       -               34,999             89,148              144,028
Income (loss) from operations           214,899                    157,027                 108,683              305,264            (72,099)             713,774
Depreciation and amortization            53,094                     27,677                  29,592               82,210             10,072              202,645
Stock compensation expense                    -                          -                       -                2,142             28,798               30,940

Adjusted EBITDA                   $     267,993            $       184,704          $      138,275          $   389,616          $ (33,229)         $   947,359
Adjusted EBITDA margin                     11.9    %                  21.7  %                 12.8  %              22.5  %                N/M              15.3  %


                                                                                For the Year Ended December 31, 2020
                                   Critical Illness          Rehabilitation            Outpatient             Concentra             Other               Total
                                  Recovery Hospital             Hospital             Rehabilitation
                                                                                           (in thousands)
Revenue                           $   2,077,499            $       734,673          $      919,913          $ 1,501,434          $ 298,194          $ 5,531,713
Operating expenses                   (1,735,072)                  (581,470)               (840,749)          (1,252,200)          (438,918)          (4,848,409)
Depreciation and amortization           (51,531)                   (27,727)                (29,009)             (87,865)            (9,527)            (205,659)
Other operating income                        -                          -                       -                1,146             88,866               90,012
Income (loss) from operations           290,896                    125,476                  50,155              162,515            (61,385)             567,657
Depreciation and amortization            51,531                     27,727                  29,009               87,865              9,527              205,659
Stock compensation expense                    -                          -                       -                2,512             24,738               27,250

Adjusted EBITDA                   $     342,427            $       153,203          $       79,164          $   252,892          $ (27,120)         $   800,566
Adjusted EBITDA margin                     16.5    %                  20.9  %                  8.6  %              16.8  %                N/M              14.5  %




                                       56

--------------------------------------------------------------------------------

Table of Contents

The following tables summarize the changes in our segment performance measures
for the year-to-date periods specified below.

                                                                                            2022 Compared to 2021
                              Critical Illness                                           Outpatient
                                  Recovery           Rehabilitation Hospital           Rehabilitation                Concentra                 Other                 Total
                                  Hospital
Change in revenue                      (0.6) %                        7.9  %                        3.8  %                  (0.4) %               14.0  %                 2.1  %
Change in income (loss) from
operations                            (76.8) %                        8.4  %                      (36.3) %                 (15.3) %                   N/M               (43.5) %
Change in Adjusted EBITDA             (58.5) %                        7.2  %                      (26.3) %                 (14.2) %                   N/M               (31.7) %


                                                                                            2021 Compared to 2020
                              Critical Illness                                           Outpatient
                                  Recovery           Rehabilitation Hospital           Rehabilitation                Concentra                 Other                 Total
                                  Hospital
Change in revenue                       8.1  %                       15.6  %                       17.9  %                  15.4  %               (2.1) %               12.2  %
Change in income (loss) from
operations                            (26.1) %                       25.1  %                      116.7  %                  87.8  %                   N/M               25.7  %
Change in Adjusted EBITDA             (21.7) %                       20.6  %                       74.7  %                  54.1  %                   N/M               18.3  %


_______________________________________________________________________________

N/M  Not meaningful.

Significant Events

Dividend Payments

On February 17, 2022, May 5, 2022, August 2, 2022, and November 2, 2022, our
board of directors declared cash dividends, each in the amount of $0.125 per
share. Cash dividends totaling $64.6 million were paid during the year ended
December 31, 2022.

Financing Transactions

On February 21, 2023, Select entered into Amendment No. 6 to the credit
agreement. Amendment No. 6 extended the maturity date on $530.0 million of the
total borrowing capacity of $650.0 million under the revolving facility to March
6, 2025; however, in the event that our term loan is not refinanced by January
3, 2025, the maturity date for those revolving borrowings will be January 3,
2025.


                                       57

--------------------------------------------------------------------------------

Table of Contents

Regulatory Changes


The Medicare program reimburses healthcare providers for services furnished to
Medicare beneficiaries, which are generally persons age 65 and older, those who
are chronically disabled, and those suffering from end stage renal disease. The
program is governed by the Social Security Act of 1965 and is administered
primarily by the Department of Health and Human Services and CMS. Revenues from
providing services to patients covered under the Medicare program represented
approximately 25%, 23%, and 23% of our revenue for the years ended December 31,
2020, 2021, and 2022, respectively.

The Medicare program reimburses various types of providers using different
payment methodologies. Those payment methodologies are complex and are described
elsewhere in this report under "Business-Government Regulations." The following
is a discussion of some of the more significant healthcare regulatory changes
that have affected our financial performance in the periods covered by this
report or are likely to affect our financial performance and financial condition
in the future.

Federal Health Care Program Changes in Response to the COVID-19 Pandemic


On January 31, 2020, HHS declared a public health emergency under section 319 of
the Public Health Service Act, 42 U.S.C. § 247d, in response to the COVID-19
outbreak in the United States. The HHS Secretary renewed the public health
emergency determination for 90-day periods effective on April 26, 2020, July 25,
2020, October 23, 2020, January 21, 2021, April 21, 2021, July 20, 2021, October
18, 2021, January 16, 2022, April 16, 2022, July 15, 2022, October 13, 2022, and
January 11, 2023. On January 30, 2023, the Biden administration announced that
it intends to extend the public health emergency declaration until May 11, 2023,
and end the emergency declaration on that date. On February 9, 2023, the HHS
Secretary issued a final 90-day renewal of the public health emergency,
effective on February 11, 2023, and confirmed that it would end on May 11, 2023.

On March 13, 2020, President Trump declared a national emergency due to the
COVID-19 pandemic and the HHS Secretary authorized the waiver or modification of
certain requirements under Medicare, Medicaid, and the CHIP program pursuant to
section 1135 of the Social Security Act. Under this authority, CMS issued a
number of blanket waivers that excuse health care providers or suppliers from
specific program requirements. The following blanket waivers, while in effect,
may impact our results of operations:

i.IRFs, IRF units, and hospitals and units applying to be classified as IRFs,
can exclude patients admitted solely to respond to the emergency from the
calculation of the "60 percent rule" thresholds to receive payment as an IRF.


ii.LTCHs are exempt from the greater-than-25-day average length of stay
requirement for all cost reporting periods that include the COVID-19 public
health emergency period. Hospitals seeking LTCH classification can exclude
patient stays from the greater-than-25-day average length of stay requirement
where the patient was admitted or discharged to meet the demands of the COVID-19
public health emergency.

iii.Medicare expanded the types of health care professionals who can furnish
telehealth services to include all those who are eligible to bill Medicare for
their professional services. This allows health care professionals who were
previously ineligible to furnish and bill for Medicare telehealth services,
including physical therapists, occupational therapists, speech language
pathologists, and others, to receive payment for Medicare telehealth services.
The Health Extenders, Improving Access to Medicare, Medicaid, and CHIP, and
Strengthening Public Health Act of 2022 extended this expansion of eligible
practitioners for telehealth services until December 31, 2024.

iv.Medicare will not require out-of-state physician and non-physician
practitioners to be licensed in the state where they are providing services when
they are licensed in another state, subject to certain conditions and state or
local licensure requirements.

v.Many requirements under the hospital conditions of participation ("CoPs") are
waived during the emergency period to give hospitals more flexibility in
treating COVID-19 patients.

vi.Hospitals can operate temporary expansion locations without meeting the
provider-based entity requirements or certain requirements in the physical
environment CoP for hospitals during the emergency. This waiver also allows
hospitals to change the status of their current provider-based department
locations to meet patient needs as part of the state or local pandemic plan.


vii.The HHS Secretary waived sanctions under the physician self-referral law
(i.e., Stark law) for certain types of remuneration and referral arrangements
that are related to a COVID-19 purpose. The OIG will also exercise enforcement
discretion to not impose administrative sanctions under the federal
anti-kickback statute for many payments covered by the Stark law waivers.

                                       58

--------------------------------------------------------------------------------

Table of Contents


Pursuant to the Coronavirus Preparedness and Response Supplemental
Appropriations Act, Public Law 116-123, CMS has waived Medicare telehealth
payment requirements during the emergency so that beneficiaries in all areas of
the country (not just rural areas) can receive telehealth services, including in
their homes, beginning on March 6, 2020.

In the Health Extenders, Improving Access to Medicare, Medicaid, and CHIP, and
Strengthening Public Health Act of 2022, Congress extended several telehealth
flexibilities that were scheduled to expire 151 days after the end of the
COVID-19 public health emergency, including the expansion of permitted
originating sites for telehealth, expansion of eligible practitioners for
furnishing telehealth, and coverage of audio-only telehealth services. As a
result, these flexibilities will remain in effect through December 31, 2024. CMS
issued additional waivers to permit more than 150 additional services to be
furnished by telehealth, allow physicians to monitor patient services remotely,
and fulfill face-to-face requirements in IRFs.

In addition to these agency actions, the CARES Act was enacted on March 27,
2020. It provides additional waivers, reimbursement, grants and other funds to
assist health care providers during the COVID-19 public health emergency. Some
of the CARES Act provisions that may impact our operations include:

i.$100 billion in appropriations for the Public Health and Social Services
Emergency Fund to be used for preventing, preparing, and responding to COVID-19
and for reimbursing "eligible health care providers for health care related
expenses or lost revenues that are attributable to coronavirus." The Paycheck
Protection Program and Health Care Enhancement Act, Public Law 116-139, added
$75 billion to this fund. The Consolidated Appropriations Act, 2021, added
another $3 billion to this fund. HHS began distributing these funds to providers
in April 2020. HHS initially allocated funds for a general distribution to
providers that received Medicare fee-for-service payments in 2019. Later general
distributions required providers to submit an application to HHS. Other funding
was allocated for targeted distributions for specific provider types. Recipients
of payments must report data to HHS on the use of the funds via an online portal
by specific deadlines established by HHS based on the date of the payment. Any
funds that a provider does not apply towards expenses or lost revenue
attributable to COVID-19 must be returned to HHS within 30 calendar days after
the end of the applicable reporting period. All recipients of funds are subject
to audit by HHS, the HHS OIG, or the Pandemic Response Accountability Committee.
Audits may include examination of the accuracy of the data providers submitted
to HHS in their applications for payments. Additional Public Health and Social
Services Emergency Fund distributions are not expected.

ii.Expansion of the Accelerated and Advance Payment Program to advance three
months of payments to Medicare providers. CMS has the ability to recoup the
advanced payments through future Medicare claims. Section 2501 of the Continuing
Appropriations Act, 2021 and Other Extensions Act, Public Law 116-159, modified
the terms of repayment so that a provider can request no recoupment for one year
after the advanced payment was issued, followed by a 25% offset the next 11
months, and a 50% offset the last 6 months. Any amounts that remain unpaid after
29 months will be subject to a 4% interest rate (instead of 10.25%). CMS began
recouping advance payments on March 30, 2021, but the actual date for each
provider is based on the first anniversary of when the provider received the
first payment. CMS publishes repayment data every six months.

iii.Temporary suspension of the 2% cut to Medicare payments due to sequestration
so that, for the period of May 1, 2020, to December 31, 2020, the Medicare
program would be exempt from any sequestration order. The Consolidated
Appropriations Act, 2021, extended this temporary suspension of the 2%
sequestration cut through March 31, 2021. The Medicare sequester relief bill,
which became Public Law 117-7, extended the temporary suspension of the
sequestration cut again, through December 31, 2021. To pay for the continued
suspension of the sequestration cuts through December 31, 2021, Congress
increased the sequestration cut that will apply in fiscal year 2030. The
Protecting Medicare and American Farmers from Sequester Cuts Act, signed into
law by President Biden on December 10, 2021, further extended the suspension of
the sequestration cut through March 31, 2022, and reduced the sequestration cut
to 1% from April 1, 2022, through June 30, 2022. The full 2% sequestration cut
resumed on July 1, 2022. To pay for this relief, Congress increased the
sequestration cut to Medicare payments to 2.25% for the first six months of
fiscal year 2030 and to 3% for the final six months of fiscal year 2030. The
same legislation defers an across-the-board 4% payment cut due to the American
Rescue Plan from the FY 2022 Statutory Pay-As-You-Go ("PAYGO") scorecard to the
FY 2023 PAYGO scorecard. Congress subsequently delayed the 4% PAYGO payment cut
for an additional two years, through the end of 2024, in the Consolidated
Appropriations Act, 2023, Public Law 117-328.

iv.Two waivers of Medicare statutory requirements regarding site neutral payment
to LTCHs. The first waives the LTCH discharge payment percentage requirement
(i.e., 50% rule) for the cost reporting period(s) that include the emergency
period. The second waives application of the site neutral payment rate so that
all LTCH cases admitted during the emergency period will be paid the LTCH-PPS
standard federal rate.

                                       59

--------------------------------------------------------------------------------

Table of Contents


v.Waiver of the IRF 3-hour rule so that IRF services provided during the public
health emergency period do not need to meet the coverage requirement that
patients receive at least 3 hours of therapy a day or 15 hours of therapy per
week.

vi.Broader waiver authority for HHS under section 1135 of the Social Security
Act to issue additional telehealth waivers.

The CARES Act also provides for a 20% increase in the payment weight for
Medicare payments to hospitals paid under the IPPS for treating COVID-19
patients.

Medicare Reimbursement of LTCH Services


The following is a summary of significant regulatory changes to the Medicare
prospective payment system for our critical illness recovery hospitals, which
are certified by Medicare as LTCHs, which have affected our results of
operations, as well as the policies and payment rates that may affect our future
results of operations. Medicare payments to our critical illness recovery
hospitals are made in accordance with LTCH-PPS.

Fiscal Year 2021. On September 18, 2020, CMS published the final rule updating
policies and payment rates for the LTCH-PPS for fiscal year 2021 (affecting
discharges and cost reporting periods beginning on or after October 1, 2020
through September 30, 2021). Certain errors in the final rule were corrected in
a document published December 7, 2020. The standard federal rate was set at
$43,755, an increase from the standard federal rate applicable during fiscal
year 2020 of $42,678. The update to the standard federal rate for fiscal year
2021 included a market basket increase of 2.3% with no productivity adjustment.
The standard federal rate also included an area wage budget neutrality factor of
1.0016837. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS
was set at $27,195, an increase from the fixed-loss amount in the 2020 fiscal
year of $26,778. The fixed-loss amount for high cost outlier cases paid under
the site-neutral payment rate was set at $29,064, an increase from the
fixed-loss amount in the 2020 fiscal year of $26,552.

Fiscal Year 2022. On August 13, 2021, CMS published the final rule updating
policies and payment rates for the LTCH-PPS for fiscal year 2022 (affecting
discharges and cost reporting periods beginning on or after October 1, 2021
through September 30, 2022). The standard federal rate was set at $44,714, an
increase from the standard federal rate applicable during fiscal year 2021 of
$43,755. The update to the standard federal rate for fiscal year 2022 included a
market basket increase of 2.6%, less a productivity adjustment of 0.7%. The
standard federal rate also included an area wage budget neutrality factor of
1.002848. As a result of the CARES Act, all LTCH cases are paid at the standard
federal rate during the public health emergency. The fixed-loss amount for high
cost outlier cases paid under LTCH-PPS was set at $33,015, an increase from the
fixed-loss amount in the 2021 fiscal year of $27,195. The fixed-loss amount for
high cost outlier cases paid under the site-neutral payment rate was set at
$30,988, an increase from the fixed-loss amount in the 2021 fiscal year of
$29,064.

Fiscal Year 2023. On August 10, 2022, CMS published the final rule updating
policies and payment rates for the LTCH-PPS for fiscal year 2023 (affecting
discharges and cost reporting periods beginning on or after October 1, 2022,
through September 30, 2023). Certain errors in the final rule were corrected in
documents published November 4, 2022, and December 13, 2022. The standard
federal rate for fiscal year 2023 is $46,433, an increase from the standard
federal rate applicable during fiscal year 2022 of $44,714. The update to the
standard federal rate for fiscal year 2023 includes a market basket increase of
4.1%, less a productivity adjustment of 0.3%. The standard federal rate also
includes an area wage budget neutrality factor of 1.0004304. As a result of the
CARES Act, all LTCH cases are paid at the standard federal rate during the
public health emergency. Once the public health emergency ends, which is
expected to occur on May 11, 2023, CMS will return to using the site-neutral
payment rate for reimbursement of cases that do not meet the LTCH patient
criteria. The fixed-loss amount for high cost outlier cases paid under LTCH-PPS
is $38,518, an increase from the fixed-loss amount in the 2022 fiscal year of
$33,015. The fixed-loss amount for high cost outlier cases paid under the
site-neutral payment rate is $38,788, an increase from the fixed-loss amount in
the 2022 fiscal year of $30,988.


                                       60

--------------------------------------------------------------------------------

Table of Contents

Medicare Reimbursement of IRF Services


The following is a summary of significant regulatory changes to the Medicare
prospective payment system for our rehabilitation hospitals, which are certified
by Medicare as IRFs, which have affected our results of operations, as well as
the policies and payment rates that may affect our future results of operations.
Medicare payments to our rehabilitation hospitals are made in accordance with
IRF-PPS.

Fiscal Year 2021. On August 10, 2020, CMS published the final rule updating
policies and payment rates for the IRF-PPS for fiscal year 2021 (affecting
discharges and cost reporting periods beginning on or after October 1, 2020
through September 30, 2021). The standard payment conversion factor for
discharges for fiscal year 2021 was set at $16,856, an increase from the
standard payment conversion factor applicable during fiscal year 2020 of
$16,489. The update to the standard payment conversion factor for fiscal year
2021 included a market basket increase of 2.4% with no productivity adjustment.
CMS decreased the outlier threshold amount for fiscal year 2021 to $7,906 from
$9,300 established in the final rule for fiscal year 2020.

Fiscal Year 2022. On August 4, 2021, CMS published the final rule updating
policies and payment rates for the IRF-PPS for fiscal year 2022 (affecting
discharges and cost reporting periods beginning on or after October 1, 2021
through September 30, 2022). The standard payment conversion factor for
discharges for fiscal year 2022 was set at $17,240, an increase from the
standard payment conversion factor applicable during fiscal year 2021 of
$16,856. The update to the standard payment conversion factor for fiscal year
2022 included a market basket increase of 2.6%, less a productivity adjustment
of 0.7%. CMS increased the outlier threshold amount for fiscal year 2022 to
$9,491 from $7,906 established in the final rule for fiscal year 2021.

Fiscal Year 2023. On August 1, 2022, CMS published the final rule updating
policies and payment rates for the IRF-PPS for fiscal year 2023 (affecting
discharges and cost reporting periods beginning on or after October 1, 2022,
through September 30, 2023). The standard payment conversion factor for
discharges for fiscal year 2023 was set at $17,878, an increase from the
standard payment conversion factor applicable during fiscal year 2022 of
$17,240. The update to the standard payment conversion factor for fiscal year
2023 included a market basket increase of 4.2%, less a productivity adjustment
of 0.3%. CMS increased the outlier threshold amount for fiscal year 2023 to
$12,526 from $9,491 established in the final rule for fiscal year 2022.

Medicare Reimbursement of Outpatient Rehabilitation Clinic Services


The Medicare program reimburses outpatient rehabilitation providers based on the
MPFS. Outpatient rehabilitation providers may enroll in Medicare as
institutional outpatient rehabilitation facilities (i.e., rehab agencies) or
individual physical or occupational therapists in private practice. The majority
of our providers are reimbursed through enrolled rehab agencies while the
remaining balance of our clinicians are enrolled as individual physical or
occupational therapists in private practice.

On an annual basis, our provider reimbursement under the MPFS is subject to
changes by CMS, which may include adjustments in our reimbursement based on
performance under the MIPS, and additional incentives for participation in APMs.
Historically, outpatient rehabilitation providers were not eligible to
participate in the MIPS program. In 2019, CMS added physical and occupational
therapists in private practice to the list of MIPS eligible clinicians. For
enrolled therapists in private practice, payments under the MPFS are subject to
adjustment in a later year based on their performance in MIPS according to
established performance standards. Calendar year 2021 was the first year that
payments were adjusted, based upon the therapist's performance under MIPS in
2019. Providers in facility-based outpatient therapy settings, including rehab
agencies, are excluded from MIPS eligibility and therefore not subject to this
payment adjustment.

As required under the MACRA, a 0.0% percent update will be applied each year to
the fee schedule payment rates for therapy services provided in 2020 through
2025, subject to adjustments under MIPS and APMs. In 2026 and subsequent years,
eligible professionals participating in APMs who meet certain criteria would
receive annual updates of 0.75%, while all other professionals would receive
annual updates of 0.25%. Each year from 2019 through 2024 eligible clinicians
who receive a significant share of their revenues through an advanced APM (such
as accountable care organizations or bundled payment arrangements) that involves
risk of financial losses and a quality measurement component will receive a 5%
bonus. The bonus payment for APM participation is intended to encourage
participation and testing of new APMs and to promote the alignment of incentives
across payors. To date, none of our outpatient rehabilitation providers
participate in qualified APMs.

In the 2020 MPFS final rule, CMS revised coding, documentation guidelines, and
increased the valuation for the E/M office visit codes, beginning in 2021.
Because the MPFS is statutorily required to be budget-neutral, any revaluation
of E/M services that will increase spending by more than $20 million requires a
budget neutrality adjustment. To increase values for the E/M codes while
maintaining budget neutrality under the fee schedule, CMS cut the values of
other codes to make up the difference, beginning in 2021.

                                       61

--------------------------------------------------------------------------------

Table of Contents


In the 2021 MPFS final rule, CMS increased the values for the E/M office visit
codes and cuts to other specialty codes to maintain budget neutrality. As a
result, therapy services provided in our outpatient rehabilitation clinics
received an estimated 3.6% decrease in payment from Medicare in calendar year
2021. The Consolidated Appropriations Act, 2021, provided relief in the form of
a one-time 3.75% increase in payments in calendar year 2021 for therapy services
and other services paid under the MPFS.

In the calendar year 2022 MPFS final rule, CMS announced that Medicare payments
for the therapy specialty were expected to decrease 1% in 2022. After CMS issued
the final rule, Congress passed the Protecting Medicare and American Farmers
from Sequester Cuts Act, which provided in Section 3 a one-time 3% increase in
payments in calendar year 2022 to offset most of the 3.75% cut to payments for
therapy services and other services paid under the MPFS. In the final rule, CMS
also adopted its plan to transition the MIPS program to MVPs. CMS will begin the
transition to MVPs in 2023 with an initial set of MVPs in which reporting is
voluntary. CMS plans to develop more MVPs from 2024 to 2027 and is considering
that MVP reporting would become mandatory in 2028.

In the calendar year 2023 MPFS final rule, CMS announced that it calculated the
payment rates for the MPFS as if the 3% payment increase in calendar year 2022
from the Protecting Medicare and American Farmers from Sequester Cuts Act was
never applied. The statute stated that the 3% payment increase for 2022 shall
not be taken into account in determining the payment rates for subsequent years.
As a result, physician fee schedule payments were expected to decrease 4.5% in
2023. CMS stated in the final rule that it expects that its policies for 2023
would result in a 1% decrease in Medicare payments for the therapy specialty,
but this decrease did not account for the effects of the end of the 3% payment
increase from 2022. However, Congress passed the Consolidated Appropriations
Act, 2023, which requires the Secretary to increase 2023 physician fee schedule
payments by 2.5% and 2024 payments by 1.25%. As a result, payments under the
2023 MPFS physician fee schedule will decrease by 2% in 2023. Medicare payments
were also due to decrease by an additional 4% in 2023 due to mandatory cuts
required under the PAYGO Act of 2010. The Consolidated Appropriations Act, 2023,
further delays PAYGO until 2025. The calendar year 2023 final rule also includes
further development of MVPs. First, CMS revised the first set of seven MVPs that
it adopted in the calendar year 2022 final rule. CMS removed certain improvement
activities from these seven MVPs and added other quality measures for voluntary
reporting by participants in these MVPs. In addition, CMS added five new MVPs
that will be available for voluntary reporting for the calendar year 2023
performance period.

Modifiers to Identify Services of Physical Therapy Assistants or Occupational
Therapy Assistants


In the MPFS final rule for calendar year 2019, CMS established two new modifiers
(CQ and CO) to identify services furnished in whole or in part by PTAs or OTAs.
These modifiers were mandated by the Bipartisan Budget Act of 2018, which
requires that claims for outpatient therapy services furnished in whole or part
by therapy assistants on or after January 1, 2020 include the appropriate
modifier. In the final 2020 MPFS rule, CMS clarified that when the physical
therapist is involved for the entire duration of the service and the PTA
provides skilled therapy alongside the physical therapist, the CQ modifier is
not required. Also, when the same service (code) is furnished separately by the
physical therapist and PTA, CMS will apply the de minimis standard to each
15-minute unit of codes, not on the total physical therapist and PTA time of the
service, allowing the separate reporting, on two different claim lines, of the
number of units to which the new modifiers apply and the number of units to
which the modifiers do not apply. In the calendar year 2022 MPFS final rule, CMS
implemented the final part of the requirements in the Bipartisan Budget Act of
2018 regarding PTA and OTA services. For dates of service on and after January
1, 2022, CMS will pay for physical therapy and occupational therapy services
provided by PTAs and OTAs at 85% of the otherwise applicable Part B payment
amount. CMS also modified the de minimis standard for calendar year 2022.
Specifically, CMS will allow a timed service to be billed without the CQ or CO
modifier when a PTA or OTA participates in providing care, but the physical
therapist or occupational therapist meets the Medicare billing requirements
without including the PTA's or OTA's minutes. This occurs when the physical
therapist or occupational therapist provides more minutes than the 15-minute
midpoint.



                                       62

--------------------------------------------------------------------------------

Table of Contents

Critical Accounting Estimates

Revenue Recognition and Accounts Receivable

Our principal revenue source comes from providing healthcare services to
patients. Patient service revenues are recognized at an amount equal to the
consideration we expect to be entitled to in exchange for providing healthcare
services to our patients. Revenue earned from these services is variable in
nature, as we are required to make judgments that impact the transaction price.


We determine the transaction price for services provided to patients who are
Medicare beneficiaries using Medicare's prospective payment systems and other
payment methods. The expected payment is determined by the level of clinical
services provided and is sensitive to the patient's length of stay.
Additionally, we are paid by various other non-Medicare payor sources including,
but not limited to, insurance companies (including Medicare Advantage plans),
state Medicaid programs, workers' compensation programs, health maintenance
organizations, preferred provider organizations, other managed care companies
and employers, as well as patients themselves. The transaction price for
services provided to non-Medicare patients include amounts prescribed by state
and federal fee schedules, negotiated contracted amounts, or usual and customary
amounts associated with the specific payor or based on the service provided. We
apply a portfolio approach in determining revenues for certain homogeneous
non-Medicare patient populations.

There is variability in the transaction price for services provided to our
patients, as the transaction price is impacted by several factors, such as the
patient's condition and length of stay, which in turn impact the payment we
expect to receive for providing such services. Variable consideration included
in the transaction price is inclusive of our estimates of implicit discounts and
other adjustments related to timely filing and documentation denials, out of
network adjustments, and medical necessity denials, which are estimated using
our historical experience. We are also subject to regular post-payment
inquiries, investigations, and audits of the claims we submit for services
provided. Some claims can take several years for resolution and may result in
adjustments to the transaction price. Management includes in its estimates of
the transaction price its expectations for these types of adjustments such that
the amount of cumulative revenue recognized will not be subject to significant
reversal in future periods. Historically, adjustments arising from a change in
the transaction price have not been significant.

Our accounts receivable is reported at an amount equal to the amount we expect
to collect for providing healthcare services to our patients. Because our
accounts receivable is typically paid for by highly-solvent, creditworthy
payors, such as Medicare, other governmental programs, and highly-regulated
commercial insurers on behalf of the patient, our credit losses are infrequent
and insignificant in nature; as such, we generally do not recognize allowances
for expected credit losses.

Insurance Risk Programs

Under a number of our insurance programs, which include our employee health
insurance, workers' compensation, and professional malpractice liability
insurance programs, we are liable for a portion of our losses before we can
attempt to recover from the applicable insurance carrier. We accrue for losses
under an occurrence-based approach, whereby we estimate the losses that will be
incurred in a respective accounting period. The estimate of losses includes
actuarial loss projections of both known claims and incurred but not reported
claims. These estimates are based on specific claim facts, claim frequency and
severity, payment patterns for historical claims, and estimates of fees for
outside counsel. In addition to the actuarial loss projections, insurance
premiums and out-of-pocket expenses for the administration and analysis of
claims are included in the estimate of losses accrued in a respective accounting
period.

We monitor these programs quarterly and revise our estimates as necessary to
take into account additional information. We recorded a liability of $173.5
million and $192.3 million for our estimated losses under these insurance
programs at December 31, 2021 and 2022, respectively. We also recorded insurance
proceeds receivable of $14.5 million and $13.1 million at December 31, 2021 and
2022, respectively, for liabilities which exceed our deductibles and
self-insured retention limits and are recoverable through our insurance
policies.








                                       63

--------------------------------------------------------------------------------

Table of Contents

Goodwill


We operate four reporting units which include the critical illness recovery
hospital reporting unit, the rehabilitation hospital reporting unit, the
outpatient rehabilitation reporting unit, and the Concentra reporting unit. We
assign goodwill to our reporting units based upon the specific nature of the
business acquired or, when a business combination contains business components
related to more than one reporting unit, goodwill is assigned to each reporting
unit based upon an allocation determined by the relative fair values of the
business acquired. When we dispose of a business, we allocate a portion of the
reporting unit's goodwill to that business based on the relative fair values of
the portion of the reporting unit being disposed of and the portion of the
reporting unit remaining. We evaluate our reporting units on an annual basis
and, if our reporting units are reorganized, we reassign goodwill based on the
relative fair values of the new reporting units.

We have elected to perform our annual goodwill impairment assessments as of
October 1. We also test goodwill for impairment when events or conditions occur
that might suggest a possible impairment. These events or conditions could
include a significant change in the business environment, the regulatory
environment, or legal factors; a current period operating or cash flow loss
combined with a history of such losses or a projection of continuing losses; or
a sale or disposition of a significant portion of a reporting unit.

We performed quantitative impairment assessments as of October 1, 2022, to
assess the impact of rising interest rates and rising costs, particularly our
labor costs, on the estimated fair values our reporting units. We considered
both the income and market approaches in determining the fair value of our
reporting units. Included in the income approach, specific for each reporting
unit, are assumptions regarding revenue growth rates, future Adjusted EBITDA
margin estimates, the industry's weighted average cost of capital, and industry
specific, market observable implied Adjusted EBITDA multiples. We also include
estimated residual values at the end of the forecast period and future capital
expenditure requirements. In establishing our assumptions, we consider current
industry and market conditions, historical financial performance, including our
revenue, earnings, and operating cash flow growth trends, cost factors,
including the effects of inflation and rising prices, and the regulatory
environment, including reimbursement and compliance requirements such as those
that exist under the Medicare program. If any one of the above assumptions or
judgments used to estimate the fair value of our reporting units fail to
materialize, the resulting decline in our estimated fair value could result in
an impairment charge to the goodwill associated with any one of the reporting
units.

Our annual assessment did not indicate that goodwill impairment was likely for
any of our reporting units. We did not identify any goodwill impairment events
during the quarter ended December 31, 2022.

We have recorded total goodwill of $3.5 billion at December 31, 2022, of which
$1.2 billion related to our critical illness recovery hospital reporting unit,
$442.2 million related to our rehabilitation hospital reporting unit, $665.0
million related to our outpatient rehabilitation reporting unit, and $1.2
billion related to the Concentra reporting unit.






                                       64

--------------------------------------------------------------------------------

Table of Contents

Operating Statistics


The following table sets forth operating statistics for each of our segments for
the periods presented. The operating statistics reflect data for the period of
time we managed these operations. Our operating statistics include metrics we
believe provide relevant insight about the number of facilities we operate,
volume of services we provide to our patients, and average payment rates for
services we provide. These metrics are utilized by management to monitor trends
and performance in our businesses and therefore may be important to investors
because management may assess our performance based in part on such metrics.
Other healthcare providers may present similar statistics, and these statistics
are susceptible to varying definitions. Our statistics as presented may not be
comparable to other similarly titled statistics of other companies.

                                                                            

For the Year Ended December 31,

                                                                         2020                  2021                 2022
Critical illness recovery hospital data:
Number of consolidated hospitals-start of period(1)                         100                    99                  104
Number of hospitals acquired                                                  1                     6                    2
Number of hospital start-ups                                                  -                     -                    1
Number of hospitals closed/sold                                              (2)                   (1)                  (4)
Number of consolidated hospitals-end of period(1)                            99                   104                  103

Available licensed beds(3)                                                4,362                 4,518                4,386
Admissions(3)(4)                                                         37,456                37,921               36,594
Patient days(3)(5)                                                    1,111,756             1,133,039            1,127,911
Average length of stay (days)(3)(6)                                          30                    30                   31
Revenue per patient day(3)(7)                                       $     1,858           $     1,972          $     1,973
Occupancy rate(3)(8)                                                         71   %                71  %                69  %
Percent patient days-Medicare(3)(9)                                          45   %                38  %                39  %
Rehabilitation hospital data:
Number of consolidated hospitals-start of period(1)                          19                    19                   20
Number of hospitals acquired                                                  1                     1                    -
Number of hospital start-ups                                                  -                     -                    -
Number of hospitals closed/sold                                              (1)                    -                    -
Number of consolidated hospitals-end of period(1)                            19                    20                   20
Number of unconsolidated hospitals managed-end of period(2)                  11                    10                   11
Total number of hospitals (all)-end of period                                30                    30                   31
Available licensed beds(3)                                                1,311                 1,361                1,391
Admissions(3)(4)                                                         25,081                28,868               29,736
Patient days(3)(5)                                                      370,833               414,701              430,547
Average length of stay (days)(3)(6)                                          15                    14                   15
Revenue per patient day(3)(7)                                       $     1,793           $     1,868          $     1,953
Occupancy rate(3)(8)                                                         78   %                83  %                85  %
Percent patient days-Medicare(3)(9)                                          48   %                49  %                48  %
Outpatient rehabilitation data:
Number of consolidated clinics-start of period                            1,461                 1,503                1,572
Number of clinics acquired                                                   17                    33                   30
Number of clinic start-ups                                                   55                    53                   44
Number of clinics closed/sold                                               (30)                  (17)                 (24)
Number of consolidated clinics-end of period                              1,503                 1,572                1,622
Number of unconsolidated clinics managed-end of period                      285                   309                  306
Total number of clinics (all)-end of period                               1,788                 1,881                1,928
Number of visits(3)(10)                                               7,593,344             9,193,624            9,573,980
Revenue per visit(3)(11)                                            $       104           $       102          $       103



                                       65

--------------------------------------------------------------------------------

Table of Contents

For the Year Ended December 31,

                                                                  2020                  2021                  2022
Concentra data:
Number of consolidated centers-start of period                        521                   517                   518
Number of centers acquired                                              6                     6                    21
Number of center start-ups                                              1                     2                     4
Number of centers closed/sold                                         (11)                   (7)                   (3)
Number of consolidated centers-end of period                          517                   518                   540
Number of onsite clinics operated-end of period                       134                   134                   147

Number of visits(3)(10)                                        10,627,904            12,052,724            12,579,468
Revenue per visit(3)(11)                                     $        123          $        125          $        127

_______________________________________________________________________________

(1)Represents the number of hospitals included in our consolidated financial
results at the end of each period presented.

(2)Represents the number of hospitals which are managed by us at the end of each
period presented. We have minority ownership interests in these businesses.

(3)Data excludes locations managed by the Company. For purposes of our Concentra
segment, onsite clinics are excluded.

(4)Represents the number of patients admitted to our hospitals during the
periods presented.

(5)Each patient day represents one patient occupying one bed for one day during
the periods presented.


(6)Represents the average number of days in which patients were admitted to our
hospitals. Average length of stay is calculated by dividing the number of
patient days, as presented above, by the number of patients discharged from our
hospitals during the periods presented.

(7)Represents the average amount of revenue recognized for each patient day.
Revenue per patient day is calculated by dividing patient service revenues,
excluding revenues from certain other ancillary and outpatient services provided
at our hospitals, by the total number of patient days.

(8)Represents the portion of our hospitals being utilized for patient care
during the periods presented. Occupancy rate is calculated using the number of
patient days, as presented above, divided by the total number of bed days
available during the period. Bed days available is derived by adding the daily
number of available licensed beds for each of the periods presented.

(9)Represents the portion of our patient days which are paid by Medicare. The
Medicare patient day percentage is calculated by dividing the total number of
patient days which are paid by Medicare by the total number of patient days, as
presented above.

(10)Represents the number of visits in which patients were treated at our
outpatient rehabilitation clinics and Concentra centers during the periods
presented. COVID-19 screening and testing services provided by our Concentra
segment are not included in these figures.


(11)Represents the average amount of revenue recognized for each patient visit.
Revenue per visit is calculated by dividing patient service revenue, excluding
revenues from certain other ancillary services, by the total number of visits.
For purposes of this computation for our Concentra segment, patient service
revenue does not include onsite clinics or revenues generated from COVID-19
screening and testing services.

                                       66

--------------------------------------------------------------------------------

Table of Contents

Results of Operations

The following table outlines selected operating data as a percentage of revenue
for the periods indicated:

For the Year Ended December 31,

                                                                    2020                     2021                     2022
Revenue                                                                100.0  %                 100.0  %                 100.0  %
Costs and expenses:
Cost of services, exclusive of depreciation and
amortization(1)                                                         85.2                     85.2                     88.4
General and administrative                                               2.5                      2.4                      2.4
Depreciation and amortization                                            3.6                      3.2                      3.3
Total costs and expenses                                                91.3                     90.8                     94.1
Other operating income                                                   1.6                      2.3                      0.5
Income from operations                                                  10.3                     11.5                      6.4

Equity in earnings of unconsolidated subsidiaries                        0.5                      0.7                      0.4
Gain on sale of businesses                                               0.2                      0.0                        -
Interest income                                                            -                      0.1                        -
Interest expense                                                        (2.7)                    (2.2)                    (2.7)
Income before income taxes                                               8.3                     10.1                      4.1
Income tax expense                                                       2.1                      2.0                      1.0
Net income                                                               6.2                      8.1                      3.1
Net income attributable to non-controlling interests                     1.5                      1.6                      0.6

Net income attributable to Select Medical Holdings
Corporation

                                                              4.7  %                   6.5  %                   2.5  %


_______________________________________________________________________________

(1)Cost of services includes salaries, wages and benefits, operating supplies,
lease and rent expense, and other operating costs.

                                       67

--------------------------------------------------------------------------------

Table of Contents


The following table summarizes selected financial data by segment for the
periods indicated:

                                                              Year Ended December 31,
                                                                                                                   % Change                   % Change
                                                   2020                 2021                 2022                2020 - 2021                2021 - 2022
                                                                                    (in thousands, except percentages)
Revenue:
Critical illness recovery hospital            $ 2,077,499          $ 2,246,772          $ 2,234,132                        8.1  %                    (0.6) %
Rehabilitation hospital                           734,673              849,340              916,763                       15.6                        7.9
Outpatient rehabilitation                         919,913           
1,084,361            1,125,282                       17.9                        3.8
Concentra                                       1,501,434            1,732,041            1,724,359                       15.4                       (0.4)
Other(1)                                          298,194              292,001              333,002                       (2.1)                      14.0
Total Company                                 $ 5,531,713          $ 6,204,515          $ 6,333,538                       12.2  %                     2.1  %
Income (loss) from operations:(2)
Critical illness recovery hospital            $   290,896          $   214,899          $    49,779                      (26.1) %                   (76.8) %
Rehabilitation hospital                           125,476              157,027              170,220                       25.1                        8.4
Outpatient rehabilitation                          50,155              108,683               69,197                      116.7                      (36.3)
Concentra                                         162,515              305,264              258,529                       87.8                      (15.3)
Other(1)                                          (61,385)             (72,099)            (144,442)                          N/M                        N/M
Total Company                                 $   567,657          $   713,774          $   403,283                       25.7  %                   (43.5) %
Adjusted EBITDA:(2)
Critical illness recovery hospital            $   342,427          $   267,993          $   111,344                      (21.7) %                   (58.5) %
Rehabilitation hospital                           153,203              184,704              198,034                       20.6                        7.2
Outpatient rehabilitation                          79,164              138,275              101,860                       74.7                      (26.3)
Concentra                                         252,892              389,616              334,337                       54.1                      (14.2)
Other(1)                                          (27,120)             (33,229)             (98,712)                          N/M                        N/M
Total Company                                 $   800,566          $   947,359          $   646,863                       18.3  %                   (31.7) %
Adjusted EBITDA margins:(2)
Critical illness recovery hospital                   16.5  %              11.9  %               5.0  %
Rehabilitation hospital                              20.9                 21.7                 21.6
Outpatient rehabilitation                             8.6                 12.8                  9.1
Concentra                                            16.8                 22.5                 19.4
Other(1)                                                 N/M                  N/M                  N/M
Total Company                                        14.5  %              15.3  %              10.2  %
Total assets:
Critical illness recovery hospital            $ 2,213,892          $ 2,304,116          $ 2,484,542
Rehabilitation hospital                         1,148,617            1,194,136            1,200,767
Outpatient rehabilitation                       1,302,110            1,348,316            1,371,123
Concentra                                       2,400,646            2,275,345            2,281,647
Other(1)                                          590,134              238,258              327,214
Total Company                                 $ 7,655,399          $ 7,360,171          $ 7,665,293
Purchases of property and equipment:
Critical illness recovery hospital            $    49,726          $    65,690          $    79,524
Rehabilitation hospital                             7,571               13,003               14,426
Outpatient rehabilitation                          28,876               36,301               40,677
Concentra                                          50,114               46,787               45,983
Other(1)                                           10,153               18,756                9,762
Total Company                                 $   146,440          $   180,537          $   190,372

_______________________________________________________________________________

(1)Other includes our corporate administration and shared services, as well as
employee leasing services with our non-consolidating subsidiaries. Total assets
include certain non-consolidating joint ventures and minority investments in
other healthcare related businesses.

(2)For the years ended December 31, 2022, 2021, and 2020, we recognized other
operating income of $28.8 million, $144.0 million, and $90.0 million,
respectively. The impact of this income on the operating results of our segments
and other activities is outlined within the tables presented under "Summary
Financial Results."

N/M   Not meaningful.

                                       68

--------------------------------------------------------------------------------

Table of Contents

Year Ended December 31, 2022 Compared to Year Ended December 31, 2021


For the year ended December 31, 2022, we had revenue of $6,333.5 million and
income from operations of $403.3 million, as compared to revenue of $6,204.5
million and income from operations of $713.8 million for the year ended
December 31, 2021. For the year ended December 31, 2022, Adjusted EBITDA was
$646.9 million, with an Adjusted EBITDA margin of 10.2%, as compared to Adjusted
EBITDA of $947.4 million and an Adjusted EBITDA margin of 15.3% in the prior
year.

The most significant contributor to the decline in our financial performance for
the year ended December 31, 2022, as compared to the year ended December 31,
2021, was an increase in labor costs in our critical illness recovery hospital
segment. Shortages in qualified healthcare professionals, particularly critical
care nurses, resulted in an increased utilization of agency staffing at
higher-than-historical rates. In an effort to reduce our reliance on agency
staffing, we increased our recruitment of full-time staff in 2022, which
resulted in increased sign-on and incentive bonuses and increased training and
orientation costs. The Company has also focused on improving the retention of
existing staff. These investments in our personnel began to contribute to
improvements in the Adjusted EBITDA margin for the critical illness recovery
hospital segment in the fourth quarter of 2022 as compared to the first three
quarters of the year.

Revenue

Critical Illness Recovery Hospital Segment. Revenue was $2,234.1 million for the
year ended December 31, 2022, compared to $2,246.8 million for the year ended
December 31, 2021. Our patient days were 1,127,911 for the year ended
December 31, 2022, compared to 1,133,039 patient days for the year ended
December 31, 2021. Occupancy in our critical illness recovery hospitals was 69%
for the year ended December 31, 2022, compared to 71% for the year ended
December 31, 2021. Revenue per patient day was $1,973 for the year ended
December 31, 2022, compared to $1,972 for the year ended December 31, 2021. We
experienced an increase in our non-Medicare revenue per patient day during the
year ended December 31, 2022. Our Medicare revenue per patient day decreased
during the year ended December 31, 2022 as a result of a decline in patient
acuity, as well as the reinstatement of the 2.0% cut to Medicare payments due to
sequestration.

Rehabilitation Hospital Segment. Revenue increased 7.9% to $916.8 million for
the year ended December 31, 2022, compared to $849.3 million for the year ended
December 31, 2021. The increase in revenue was principally due to an increase in
revenue per patient day. Our revenue per patient day increased 4.6% to $1,953
for the year ended December 31, 2022, compared to $1,868 for the year ended
December 31, 2021. We experienced increases in both our non-Medicare and
Medicare revenue per patient day during the year ended December 31, 2022. Our
patient days increased 3.8% to 430,547 days for the year ended December 31,
2022, compared to 414,701 days for the year ended December 31, 2021. Occupancy
in our rehabilitation hospitals increased to 85% for the year ended December 31,
2022, compared to 83% for the year ended December 31, 2021.

Outpatient Rehabilitation Segment. Revenue increased 3.8% to $1,125.3 million
for the year ended December 31, 2022, compared to $1,084.4 million for the year
ended December 31, 2021. The increase in revenue was primarily attributable to
patient visits, which increased 4.1% to 9,573,980 for the year ended
December 31, 2022, compared to 9,193,624 visits for the year ended December 31,
2021. The increase in visits resulted from the acquisition and development of
clinics since December 31, 2021, as well as improvement in volume in our clinics
which operated during both the years ended December 31, 2022 and 2021. Our
revenue per visit was approximately $103 for the year ended December 31, 2022,
compared to approximately $102 for the year ended December 31, 2021, despite a
decrease in Medicare reimbursement rates.

Concentra Segment. Revenue was $1,724.4 million for the year ended December 31,
2022, compared to $1,732.0 million for the year ended December 31, 2021. The
decrease is attributable to a decline in revenue generated from COVID-19
screening and testing services provided at our centers and onsite clinics
located at employer worksites. These services contributed $20.9 million of
revenue during the year ended December 31, 2022, compared to $137.6 million
during the year ended December 31, 2021. The decline in revenue was partially
offset by increases in both revenue per visit and patient visits. Revenue per
visit increased to $127 for the year ended December 31, 2022, compared to $125
for the year ended December 31, 2021. We experienced a higher revenue per visit
due to increases in the reimbursement rates payable pursuant to certain state
fee schedules for workers' compensation visits, as well as increases in our
employer services rates, during the year ended December 31, 2022. Our patient
visits increased 4.4% to 12,579,468 for the year ended December 31, 2022,
compared to 12,052,724 visits for the year ended December 31, 2021.




                                       69

--------------------------------------------------------------------------------

Table of Contents

Operating Expenses


Our operating expenses consist principally of cost of services and general and
administrative expenses. Our operating expenses were $5,753.2 million, or 90.8%
of revenue, for the year ended December 31, 2022, compared to $5,432.1 million,
or 87.6% of revenue, for the year ended December 31, 2021. Our cost of services,
a major component of which is labor expense, was $5,600.2 million, or 88.4% of
revenue, for the year ended December 31, 2022, compared to $5,285.1 million, or
85.2% of revenue, for the year ended December 31, 2021. The increase in our
operating expenses relative to our revenue was principally attributable to the
incurrence of additional labor costs and other operating expenses within our
critical illness recovery hospital and outpatient rehabilitation segments, as
explained further within the "Adjusted EBITDA" discussion. General and
administrative expenses were $153.0 million, or 2.4% of revenue, for the year
ended December 31, 2022, compared to $147.0 million, or 2.4% of revenue, for the
year ended December 31, 2021.

Other Operating Income

For the year ended December 31, 2022, we had other operating income of $28.8
million, compared to $144.0 million for the year ended December 31, 2021. The
other operating income recognized is primarily related to the recognition of
payments received under the Provider Relief Fund for health care related
expenses and lost revenues attributable to COVID-19. Additionally, during the
year ended December 31, 2022, our critical illness recovery hospital segment
recognized $4.4 million of other operating income related to the settlement of a
business interruption insurance claim. During the year ended December 31, 2021,
our critical illness recovery hospital segment recognized $19.9 million of other
operating income related to the outcome of litigation with CMS.

Adjusted EBITDA


Critical Illness Recovery Hospital Segment. Adjusted EBITDA was $111.3 million
for the year ended December 31, 2022, compared to $268.0 million for the year
ended December 31, 2021. Our Adjusted EBITDA margin for the critical illness
recovery hospital segment was 5.0% for the year ended December 31, 2022,
compared to 11.9% for the year ended December 31, 2021. The declines in Adjusted
EBITDA and Adjusted EBITDA margin during the year ended December 31, 2022, as
compared to the year ended December 31, 2021, were principally due to increased
labor costs from our efforts to hire additional full-time staff and improve
retention of existing employees. This led to increases in sign-on and incentive
bonuses, education and orientation costs, and an increase in administrative
nursing hours during the onboarding process. As a result of these hiring
efforts, our usage of higher-cost contract labor declined throughout the year
ended December 31, 2022. Our contract registered nursing hours as a percentage
of our total registered nursing hours were 18.1%, 21.9%, 32.9%, 37.5%, and 37.5%
for the three months ended December 31, 2022, September 30, 2022, June 30, 2022,
March 31, 2022, and December 31, 2021, respectively. The decrease in our other
operating income also contributed to the declines in Adjusted EBITDA and
Adjusted EBITDA margin. Our critical illness recovery hospitals segment
recognized $4.4 million of other operating income during the year ended
December 31, 2022, compared to $19.9 million during the year ended December 31,
2021, as described further above under "Other Operating Income."

Rehabilitation Hospital Segment. Adjusted EBITDA increased 7.2% to $198.0
million for the year ended December 31, 2022, compared to $184.7 million for the
year ended December 31, 2021. Our Adjusted EBITDA margin for the rehabilitation
hospital segment was 21.6% for the year ended December 31, 2022, compared to
21.7% for the year ended December 31, 2021. The increase in Adjusted EBITDA was
driven by increases in our revenue per patient day and patient volumes, as
described further above under "Revenue." The increase was partially offset by
the incurrence of additional labor costs during the year ended December 31,
2022, as compared to the year ended December 31, 2021.

Outpatient Rehabilitation Segment. Adjusted EBITDA was $101.9 million for the
year ended December 31, 2022, compared to $138.3 million for the year ended
December 31, 2021. Our Adjusted EBITDA margin for the outpatient rehabilitation
segment was 9.1% for the year ended December 31, 2022, compared to 12.8% for the
year ended December 31, 2021. Our Adjusted EBITDA and Adjusted EBITDA margin
were affected by increases in both labor costs and other operating expenses for
the year ended December 31, 2022, as compared to the year ended December 31,
2021. The increase in labor costs was attributable to a decrease in clinical
productivity, partially due to disruptions in our workforce caused by COVID-19,
and increased contract labor usage. The increase in other operating expenses was
primarily comprised of travel and other expenses returning to pre-pandemic
levels and investments in our electronic medical records system.




                                       70

--------------------------------------------------------------------------------

Table of Contents


Concentra Segment. Adjusted EBITDA was $334.3 million for the year ended
December 31, 2022, compared to $389.6 million for the year ended December 31,
2021. Our Adjusted EBITDA margin for the Concentra segment was 19.4% for the
year ended December 31, 2022, compared to 22.5% for the year ended December 31,
2021. The declines in Adjusted EBITDA and Adjusted EBITDA margin during the year
ended December 31, 2022, as compared to the year ended December 31, 2021, were
primarily caused by a decline in revenue generated from COVID-19 screening and
testing services, as discussed above under "Revenue." The decrease in our other
operating income also contributed to the declines in Adjusted EBITDA and
Adjusted EBITDA margin. Our Concentra segment recognized $0.3 million of other
operating income during the year ended December 31, 2022, compared to
$35.0 million during the year ended December 31, 2021, as described further
above under "Other Operating Income."

Depreciation and Amortization

Depreciation and amortization expense was $205.8 million for the year ended
December 31, 2022, compared to $202.6 million for the year ended December 31,
2021
.


Income from Operations

For the year ended December 31, 2022, we had income from operations of $403.3
million, compared to $713.8 million for the year ended December 31, 2021. The
increase in labor costs and other operating expenses experienced within our
critical illness recovery hospital and outpatient rehabilitation segments were
the primary cause of the decrease in income from operations, as discussed above
under "Adjusted EBITDA." The decrease in our other operating income also
contributed to the decline in income from operations. We recognized other
operating income of $28.8 million during the year ended December 31, 2022,
compared to $144.0 million for the year ended December 31, 2021, as described
further under "Other Operating Income."

Equity in Earnings of Unconsolidated Subsidiaries


For the year ended December 31, 2022, we had equity in earnings of
unconsolidated subsidiaries of $26.4 million, compared to $44.4 million for the
year ended December 31, 2021. The earnings of the rehabilitation businesses in
which we are a minority owner were adversely affected by a decrease in Provider
Relief Fund payments recognized as income and increases in labor costs and other
operating expenses for the year ended December 31, 2022, as compared to the year
ended December 31, 2021.

Gain on Sale of Businesses

We recognized a gain of $2.2 million during the year ended December 31, 2021.
The gain resulted from the sale of a Concentra business.

Interest


Our term loan is subject to an interest rate cap, which limits the one-month
LIBOR rate to 1.0% on $2.0 billion of principal outstanding under the term loan.
The one-month LIBOR rate was 4.39% at December 31, 2022, compared to 0.10% at
December 31, 2021. The one-month LIBOR rate first exceeded 1.0% in June 2022 and
the interest rate cap has since mitigated our exposure to increases in the
one-month LIBOR rate. Interest expense was $169.1 million for the year ended
December 31, 2022, compared to $136.0 million for the year ended December 31,
2021. The increase in interest expense was caused by the borrowings we made
under our revolving facility during the year ended December 31, 2022, as well an
increase in the one-month LIBOR rate, as described further above.

For the year ended December 31, 2021, we recognized interest income of $5.4
million
related to the outcome of litigation with CMS.

Income Taxes


We recorded income tax expense of $62.6 million for the year ended December 31,
2022, which represented an effective tax rate of 24.0%. We recorded income tax
expense of $129.8 million for the year ended December 31, 2021, which
represented an effective tax rate of 20.6%. For the year ended December 31,
2022, the higher effective tax rate resulted from a greater proportion of our
income being generated in states with higher tax rates, the effect of a change
in Pennsylvania's corporate income tax rate on our net deferred tax asset, and a
greater effect of nondeductible expenses on our income before income taxes.

Refer to Note 19 - Income Taxes of the notes to our consolidated financial
statements included herein for the reconciliations of the statutory federal
income tax rate to our effective income rate for the years ended December 31,
2022
and 2021.

                                       71

--------------------------------------------------------------------------------

Table of Contents

Net Income Attributable to Non-Controlling Interests


Net income attributable to non-controlling interests was $39.0 million for the
year ended December 31, 2022, compared to $97.7 million for the year ended
December 31, 2021. The reduction in net income attributable to non-controlling
interests was principally due to a change in our ownership interest of Concentra
Group Holdings Parent. In December 2021, we acquired substantially all of the
outstanding membership interests of Concentra Group Holdings Parent. The
reduction in net income attributable to non-controlling interests was also due
to a decline in the net income of our less than wholly owned subsidiaries. Many
of these subsidiaries were impacted by increases in labor costs during the year
ended December 31, 2022, as compared to the year ended December 31, 2021.


                                       72

--------------------------------------------------------------------------------

Table of Contents

Liquidity and Capital Resources

Cash Flows for the Years Ended December 31, 2020, 2021, and 2022

In the following, we discuss cash flows from operating activities, investing
activities, and financing activities.


                                                                   For the 

Year Ended December 31,

                                                             2020                 2021                2022
Cash flows provided by operating activities            $   1,028,073          $  401,228          $  284,825
Cash flows used in investing activities                     (115,353)           (256,594)           (226,339)
Cash flows used in financing activities                     (671,541)           (647,385)            (34,890)
Net increase (decrease) in cash and cash
equivalents                                                  241,179            (502,751)             23,596
Cash and cash equivalents at beginning of period             335,882             577,061              74,310
Cash and cash equivalents at end of period             $     577,061        

$ 74,310 $ 97,906



Operating activities provided $284.8 million, $401.2 million, and $1,028.1
million of cash flows during the years ended December 31, 2022, 2021, and 2020,
respectively. The decrease in cash flows from operating activities for the year
ended December 31, 2022, as compared to the year ended December 31, 2021, was
primarily due to a reduction in our operating income. As outlined below, our
operating cash flows for the year ended December 31, 2020 benefited from the
advance payments received under the Accelerated and Advance Payment Program as
well as payments received under the Provider Relief Fund. We received
$318.1 million of advance payments under the Accelerated and Advance Payment
Program during the year ended December 31, 2020. CMS recouped $83.8 million and
$241.2 million of these payments during the years ended December 31, 2022 and
2021, respectively. During the years ended December 31, 2022, 2021, and 2020, we
received $23.8 million, $43.1 million, and $172.6 million of payments under the
Provider Relief Fund. These programs are described further in Note 22 - CARES
Act of the notes to our consolidated financial statements.

Our days sales outstanding was 55 days at December 31, 2022, 52 days at
December 31, 2021, and 56 days at December 31, 2020. Our days sales outstanding
will fluctuate based upon variability in our collection cycles and patient
volumes.


Investing activities used $226.3 million, $256.6 million, and $115.4 million of
cash flows for the years ended December 31, 2022, 2021, and 2020, respectively.
For the year ended December 31, 2022, the principal uses of cash were $190.4
million for purchases of property and equipment and $44.3 million for
investments in and acquisitions of businesses. The cash outflows were offset in
part by proceeds received from the sale of assets of $8.3 million. For the year
ended December 31, 2021, the principal uses of cash were $180.5 million for
purchases of property and equipment and $102.9 million for investments in and
acquisitions of businesses. The cash outflows were offset in part by proceeds
received from the sale of assets and business of $26.8 million. For the year
ended December 31, 2020, the principal uses of cash were $146.4 million for
purchases of property and equipment and $52.2 million for investments in and
acquisitions of businesses. We also received proceeds from the sale of assets
and business of $83.3 million.

Financing activities used $34.9 million of cash flows for the year ended
December 31, 2022. The principal uses of cash were $195.5 million for
repurchases of common stock, $64.6 million of dividend payments to common
stockholders, and $43.1 million for distributions to and purchases of
non-controlling interests. We had net borrowings of $285.0 million under our
revolving facility.


Financing activities used $647.4 million of cash flows for the year ended
December 31, 2021. The principal use of cash was $660.7 million for the purchase
of additional membership interests of Concentra Group Holdings Parent. Other
uses of cash included $79.5 million for repurchases of common stock, $73.1
million for distributions to and purchases of non-controlling interests, and
$50.6 million of dividend payments to common stockholders. We had borrowings of
$160.0 million under our revolving facility.

Financing activities used $671.5 million of cash flows for the year ended
December 31, 2020. The principal use of cash was $576.4 million for the purchase
of additional membership interests of Concentra Group Holdings Parent. We also
used $39.8 million of cash for the mandatory prepayment of term loans under our
credit facilities.




                                       73

--------------------------------------------------------------------------------

Table of Contents

Capital Resources


Working capital. We had net working capital of $116.2 million at December 31,
2022, compared to a net working capital deficit of $133.6 million at
December 31, 2021. The reduction of the working capital deficit was primarily
due to an increase in our accounts receivable, a reduction in our liability
related to the payments we received under the Accelerated and Advance Payment
Program, and an increase in the fair value of our interest rate cap contract,
which we expect to realize during 2023.

A significant component of our net working capital is our accounts receivable.
Collection of these accounts receivable is our primary source of cash and is
critical to our liquidity and capital resources. Most of our patients are
subject to healthcare coverage through third party payor arrangements, including
Medicare and Medicaid. It is our general policy to verify healthcare coverage
prior to providing services. We have credit risk associated with our accounts
receivable; however, we believe there is a remote possibility of default with
these payors.

Credit facilities.  At December 31, 2022, Select had outstanding borrowings
under its credit facilities consisting of a $2,103.4 million term loan
(excluding unamortized original issue discounts and debt issuance costs of $9.1
million). At December 31, 2022, Select had $148.5 million of availability under
its revolving facility after giving effect to $445.0 million of outstanding
borrowings and $56.5 million of outstanding letters of credit.

On the last day of each calendar quarter, Select is required to pay each lender
a commitment fee in respect of any unused commitments under the revolving
facility, which is currently 0.50% per annum and subject to adjustment based on
Select's leverage ratio, as specified in the credit agreement.

As of December 31, 2022, Select's leverage ratio (its ratio of total
indebtedness to consolidated EBITDA for the prior four consecutive fiscal
quarters), which is required to be maintained at less than 7.00 to 1.00 under
the terms of the revolving facility, was 5.96 to 1.00. We will not be required
to make a prepayment of borrowings as a result of excess cash flow for the year
ended December 31, 2022.

Our credit facilities also contain a number of other affirmative and restrictive
covenants, including limitations on mergers, consolidations and dissolutions;
sales of assets; investments and acquisitions; indebtedness; liens; affiliate
transactions; and dividends and restricted payments. Our credit facilities
contain events of default for non-payment of principal and interest when due
(subject, as to interest, to a grace period), cross-default and
cross-acceleration provisions and an event of default that would be triggered by
a change of control.

6.250% senior notes. At December 31, 2022, Select had $1,225.0 million of 6.250%
senior notes outstanding (excluding unamortized premium and debt issuance costs
of $10.6 million).

The terms of the senior notes contains covenants that, among other things, limit
Select's ability and the ability of certain of Select's subsidiaries to (i)
grant liens on its assets, (ii) make dividend payments, other distributions or
other restricted payments, (iii) incur restrictions on the ability of Select's
restricted subsidiaries to pay dividends or make other payments, (iv) enter into
sale and leaseback transactions, (v) merge, consolidate, transfer or dispose of
substantially all of their assets, (vi) incur additional indebtedness, (vii)
make investments, (viii) sell assets, including capital stock of subsidiaries,
(ix) use the proceeds from sales of assets, including capital stock of
restricted subsidiaries, and (x) enter into transactions with affiliates. These
covenants are subject to a number of exceptions, limitations and qualifications.

Stock Repurchase Program. Holdings' board of directors has authorized a common
stock repurchase program to repurchase up to $1.0 billion worth of shares of its
common stock. The common stock repurchase program will remain in effect until
December 31, 2023, unless further extended or earlier terminated by the board of
directors. Stock repurchases under this program may be made in the open market
or through privately negotiated transactions, and at times and in such amounts
as Holdings deems appropriate. Holdings funds this program with cash on hand and
borrowings under its revolving facility. During the year ended December 31,
2022, Holdings repurchased 7,883,195 shares at a cost of approximately $185.1
million, or $23.48 per share, which includes transaction costs. Since the
inception of the program through December 31, 2022, Holdings has repurchased
48,234,823 shares at a cost of approximately $600.3 million, or $12.45 per
share, which includes transaction costs. On August 16, 2022, Congress passed the
Inflation Reduction Act of 2022, which enacted a 1% excise tax on stock
repurchases that exceed $1.0 million, effective January 1, 2023.

Use of Capital Resources. We may from time to time pursue opportunities to
develop new joint venture relationships with large, regional health systems and
other healthcare providers. We also intend to open new outpatient rehabilitation
clinics and occupational health centers in local areas that we currently serve
where we can benefit from existing referral relationships and brand awareness to
produce incremental growth. In addition to our development activities, we may
grow through opportunistic acquisitions.


                                       74

--------------------------------------------------------------------------------

Table of Contents

Liquidity


We believe our internally generated cash flows and borrowing capacity under our
revolving facility will allow us to finance our operations in both the short and
long term. As of December 31, 2022, we had cash and cash equivalents of $97.9
million and $148.5 million of availability under our revolving facility, after
giving effect to $445.0 million of outstanding borrowings and $56.5 million of
outstanding letters of credit.

Our material cash requirements from known contractual and other obligations
include:

i.Debt payments, including finance lease payments - Our expected principal
payments total $3,878.2 million, with $44.4 million payable within the next
twelve months. We intend to refinance our long-term indebtedness before it
matures. Refer to Note 11 - Long-Term Debt and Notes Payable of the notes to our
consolidated financial statements included herein for additional information.

ii.Interest payments - Our expected interest payments on the 6.250% senior
notes, term loan, and revolving facility total $502.7 million, with $183.4
million
payable within the next twelve months.


Interest payments for the 6.250% senior notes were calculated using the stated
interest rate. Interest payments for the revolving facility were calculated
using 6.4%, the interest rate in effect at December 31, 2022. Interest payments
on the portion of the term loan which is subject to the provisions of our
interest rate cap agreement were calculated using a rate of 3.6%. Interest
payments on principal not subject to the provisions of the interest rate cap
agreement were calculated using a rate of 6.2%. Our interest rate cap contract
is discussed further in Item 7A. "Quantitative and Qualitative Disclosures about
Market Risk."

iii.Operating lease payments - Our expected operating lease payments total
$1,636.8 million, with $299.6 million payable within the next twelve months.
Refer to Note 6 - Leases of the notes to our consolidated financial statements
included herein for additional information.

iv.Purchase, construction, and other commitments - Our expected payments related
to purchase, construction, and other obligations total $289.6 million, with
$106.6 million payable within the next twelve months. Our purchase obligations
primarily relate to software licensing and support agreements which specify all
significant contractual terms and are legally binding and enforceable. Our
construction commitments are described further in Note 21 - Commitments and
Contingencies.

v.Insurance liabilities - Our expected payments related to our insurance
liabilities, including those for workers' compensation and professional
malpractice liabilities, total $192.3 million, with $88.3 million payable within
the next twelve months. The amounts payable within the next twelve months are
recorded in accrued other in the consolidated balance sheet as of December 31,
2022. The remaining amounts are recorded in other non-current liabilities.

vi.Other current liabilities recorded in the consolidated balance sheet as of
December 31, 2022, such as accounts payable and accrued expenses, which are not
specifically identified above.

We may from time to time seek to retire or purchase our outstanding debt through
cash purchases and/or exchanges for equity securities, in open market purchases,
privately negotiated transactions, tender offers or otherwise. Such repurchases
or exchanges, if any, may be funded from operating cash flows or other sources
and will depend on prevailing market conditions, our liquidity requirements,
contractual restrictions and other factors. The amounts involved may be
material.

Effects of Inflation


The healthcare industry is labor intensive and our largest expenses are labor
related costs. Wage and other expenses increase during periods of inflation and
when labor shortages occur in the marketplace. We have recently experienced
higher labor costs related to the current inflationary environment and
competitive labor market. In addition, suppliers have passed along rising costs
to us in the form of higher prices. We cannot predict our ability to pass along
cost increases to our customers.

Recent Accounting Pronouncements

Refer to Note 1 - Organization and Significant Accounting Policies of the notes
to our consolidated financial statements included herein for information
regarding recent accounting pronouncements.

                                       75

--------------------------------------------------------------------------------

Table of Contents

Older

6 Ways Seniors Can Prepare for a Life Insurance Medical Exam

Newer

Letter: Oh, the ills of socialism

Advisor News

  • Survey: Most Americans still feel prosperous despite economic worries
  • SEC settlement would require Tai Lopez, two others, to pay $6.8 million
  • The Gen Z money paradox
  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
More Advisor News

Annuity News

  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • Best’s Market Segment Report: AM Best Maintains Stable Outlook on US Life/Annuity Insurance Segment
  • AM Best Affirms Credit Ratings of Massachusetts Mutual Life Insurance Company and Its Subsidiaries
  • Boomers want retirement protection, but their actions don’t match their mindset
  • NAIC task force to address LTC riders
More Annuity News

Health/Employee Benefits News

  • EXPLORING INSULIN COST-SHARING CAPS FOR PATIENTS WITH PRIVATE COVERAGE
  • THE AMERICAN DIABETES ASSOCIATION FIGHTS TO MAINTAIN ACCESS TO HEALTH INSURANCE
  • Grand jury accuses veteran of making false disability claims that defrauded VA
  • States push short-term insurance as healthcare costs climb
  • Study Findings on Managed Care Are Outlined in Reports from Massachusetts General Hospital (A RUC Rescue of Primary Care?): Managed Care
More Health/Employee Benefits News

Life Insurance News

  • FORMER PRINCE GEORGE'S COUNTY INSURANCE AGENT SENTENCED FOR FELONY INSURANCE THEFT SCHEME
  • AM Best Affirms Credit Ratings of Ameriprise Financial, Inc. and Its Subsidiaries
  • AM Best Takes Various Credit Rating Actions on Certain Subsidiaries of Auto-Owners Insurance Group
  • AM Best Affirms Credit Ratings of Global Atlantic Financial Group Limited and Its Subsidiaries
  • AM Best Downgrades Credit Ratings of CICA Life Insurance Company of America
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.